全面更新的关于 SARS-CoV-2 和 COVID-19 的综述。
A Comprehensive Updated Review on SARS-CoV-2 and COVID-19.
机构信息
Division of Inflammation and Immune Pharmacology, Office of Clinical Pharmacology, Office of Translational Sciences, Center for Drug Evaluation and Research, FDA, Silver Spring, Maryland, USA.
Division of Rheumatology and Transplant Medicine, Office of Immunology and Inflammation, Office of New Drugs, Center for Drug Evaluation and Research, FDA, Silver Spring, Maryland, USA.
出版信息
J Clin Pharmacol. 2020 Aug;60(8):954-975. doi: 10.1002/jcph.1673. Epub 2020 Jun 24.
Abstract
This literature review aims to provide a comprehensive current summary of the pathogenesis, clinical features, disease course, host immune responses, and current investigational antiviral and immunomodulatory pharmacotherapies to facilitate the development of future therapies and measures for prevention and control.
摘要
本次文献综述旨在提供当前关于发病机制、临床特征、疾病进程、宿主免疫反应以及当前抗病毒和免疫调节药物治疗的全面总结，以促进未来治疗方法和预防控制措施的发展。
相似文献
1
A Comprehensive Updated Review on SARS-CoV-2 and COVID-19.全面更新的关于 SARS-CoV-2 和 COVID-19 的综述。
J Clin Pharmacol. 2020 Aug;60(8):954-975. doi: 10.1002/jcph.1673. Epub 2020 Jun 24.
2
Prevention and treatment of COVID-19 disease by controlled modulation of innate immunity.通过对固有免疫的控制调节来预防和治疗 COVID-19 疾病。
Eur J Immunol. 2020 Jul;50(7):932-938. doi: 10.1002/eji.202048693. Epub 2020 Jun 15.
3
Statin therapy and SAR-COV-2: an available and potential therapy?他汀类药物治疗与新型冠状病毒2：一种可行且有潜力的治疗方法？
Eur Heart J Cardiovasc Pharmacother. 2020 Sep 1;6(5):333-334. doi: 10.1093/ehjcvp/pvaa050.
4
COVID-19: Small-Molecule Clinical Trials Landscape.新冠病毒病（COVID-19）：小分子药物临床试验全景
Curr Top Med Chem. 2020;20(18):1577-1580. doi: 10.2174/156802662018200703154334.
5
Cytokine storm and immunomodulatory therapy in COVID-19: Role of chloroquine and anti-IL-6 monoclonal antibodies.细胞因子风暴与 COVID-19 的免疫调节治疗：氯喹和抗 IL-6 单克隆抗体的作用。
Int J Antimicrob Agents. 2020 Jun;55(6):105982. doi: 10.1016/j.ijantimicag.2020.105982. Epub 2020 Apr 16.
6
Emergence of novel coronavirus and progress toward treatment and vaccine.新型冠状病毒的出现以及治疗和疫苗的研发进展。
Rev Med Virol. 2020 Jul;30(4):e2116. doi: 10.1002/rmv.2116. Epub 2020 Jun 4.
7
[Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2): Should we target the virus, the cell or the disease?].[严重急性呼吸综合征冠状病毒2（SARS-CoV-2）：我们应该针对病毒、细胞还是疾病？]
Virologie (Montrouge). 2020 Jun 1;24(3):135-141. doi: 10.1684/vir.2020.0843.
8
COVID-19: The Need for Immunoprevention at Industrial Scale.新型冠状病毒肺炎：大规模免疫预防的必要性
Am J Trop Med Hyg. 2020 Jun;102(6):1151. doi: 10.4269/ajtmh.20-0239.
9
Audio Interview: Approaches to Covid-19 Vaccines and Antivirals.音频访谈：新冠病毒疫苗与抗病毒药物的研究方法
N Engl J Med. 2020 Apr 23;382(16):e58. doi: 10.1056/NEJMe2012889.
10
Activation of TLR7 and Innate Immunity as an Efficient Method Against COVID-19 Pandemic: Imiquimod as a Potential Therapy.激活TLR7与固有免疫作为对抗新冠疫情的有效方法：咪喹莫特作为一种潜在疗法
Front Immunol. 2020 Jun 11;11:1373. doi: 10.3389/fimmu.2020.01373. eCollection 2020.
引用本文的文献
1
Assessing the impact of enhanced hygiene precautions during the COVID-19 pandemic on surgical site infection risk in abdominal surgeries.评估 COVID-19 大流行期间强化卫生措施对腹部手术部位感染风险的影响。
BMC Surg. 2024 Sep 10;24(1):253. doi: 10.1186/s12893-024-02548-3.
2
Acute kidney injury in hospitalized patients with COVID-19: A Portuguese cohort.COVID-19 住院患者的急性肾损伤：一项葡萄牙队列研究。
Nefrologia (Engl Ed). 2021 Nov-Dec;41(6):689-698. doi: 10.1016/j.nefroe.2022.01.007.
3
Dynamics of Viral Infection and Evolution of SARS-CoV-2 Variants in the Calabria Area of Southern Italy.意大利南部卡拉布里亚地区新冠病毒感染动态及SARS-CoV-2变体的演变
Front Microbiol. 2022 Jul 28;13:934993. doi: 10.3389/fmicb.2022.934993. eCollection 2022.
4
Comparative Analysis of Circulating Levels of SARS-CoV-2 Antibodies and Inflammatory Mediators in Healthcare Workers and COVID-19 Patients.医护人员和新冠肺炎患者中 SARS-CoV-2 抗体及炎症介质循环水平的比较分析
Viruses. 2022 Feb 23;14(3):455. doi: 10.3390/v14030455.
5
The impact of transient and persistent acute kidney injury in hospital mortality in COVID-19 patients.COVID-19 患者中急性肾损伤的一过性和持续性对住院死亡率的影响。
J Bras Nefrol. 2022 Jul-Sep;44(3):310-320. doi: 10.1590/2175-8239-JBN-2021-0123.
6
Pediatric Pulmonary Function Testing in COVID-19 Pandemic and Beyond. A Position Statement From the Hellenic Pediatric Respiratory Society.新冠疫情期间及之后的儿科肺功能测试。希腊儿科呼吸学会的立场声明。
Front Pediatr. 2021 May 21;9:673322. doi: 10.3389/fped.2021.673322. eCollection 2021.
7
Is SARS-CoV-2 an Etiologic Agent or Predisposing Factor for Oral Lesions in COVID-19 Patients? A Concise Review of Reported Cases in the Literature.新型冠状病毒是COVID-19患者口腔病变的病原体还是诱发因素？文献报道病例的简要综述。
Int J Dent. 2021 May 18;2021:6648082. doi: 10.1155/2021/6648082. eCollection 2021.
8
Acute kidney injury in hospitalized patients with COVID-19: A Portuguese cohort.新冠肺炎住院患者的急性肾损伤：一项葡萄牙队列研究。
Nefrologia. 2021 Nov-Dec;41(6):689-698. doi: 10.1016/j.nefro.2021.04.002. Epub 2021 May 14.
9
Development and validation of viral load assays to quantitate SARS-CoV-2.开发和验证定量检测 SARS-CoV-2 的病毒载量检测方法。
J Virol Methods. 2021 May;291:114100. doi: 10.1016/j.jviromet.2021.114100. Epub 2021 Feb 15.
10
Tuberculosis, COVID-19, and the End Tuberculosis strategy in India.印度的结核病、新冠疫情与终结结核病战略
Lung India. 2020 Nov-Dec;37(6):467-472. doi: 10.4103/lungindia.lungindia_544_20.
本文引用的文献
1
Assessment of QT Intervals in a Case Series of Patients With Coronavirus Disease 2019 (COVID-19) Infection Treated With Hydroxychloroquine Alone or in Combination With Azithromycin in an Intensive Care Unit.评估单独使用羟氯喹或联合使用阿奇霉素在重症监护病房治疗的 2019 年冠状病毒病（COVID-19）感染患者的 QT 间期。
JAMA Cardiol. 2020 Sep 1;5(9):1067-1069. doi: 10.1001/jamacardio.2020.1787.
2
Risk of QT Interval Prolongation Associated With Use of Hydroxychloroquine With or Without Concomitant Azithromycin Among Hospitalized Patients Testing Positive for Coronavirus Disease 2019 (COVID-19).COVID-19 住院患者使用羟氯喹（无论是否联合使用阿奇霉素）导致 QT 间期延长的风险。
JAMA Cardiol. 2020 Sep 1;5(9):1036-1041. doi: 10.1001/jamacardio.2020.1834.
3
Current smoking, former smoking, and adverse outcome among hospitalized COVID-19 patients: a systematic review and meta-analysis.住院COVID-19患者中的当前吸烟、既往吸烟与不良结局：一项系统评价和荟萃分析
Ther Adv Chronic Dis. 2020 Jun 25;11:2040622320935765. doi: 10.1177/2040622320935765. eCollection 2020.
4
Interleukin-1 blockade with high-dose anakinra in patients with COVID-19, acute respiratory distress syndrome, and hyperinflammation: a retrospective cohort study.在患有新冠肺炎、急性呼吸窘迫综合征和炎症反应过度的患者中使用高剂量阿那白滞素进行白细胞介素-1阻断：一项回顾性队列研究。
Lancet Rheumatol. 2020 Jun;2(6):e325-e331. doi: 10.1016/S2665-9913(20)30127-2. Epub 2020 May 7.
5
Reduction and Functional Exhaustion of T Cells in Patients With Coronavirus Disease 2019 (COVID-19).新型冠状病毒病（COVID-19）患者 T 细胞减少和功能耗竭。
Front Immunol. 2020 May 1;11:827. doi: 10.3389/fimmu.2020.00827. eCollection 2020.
6
Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial.瑞德西韦治疗成人重症 COVID-19 的随机、双盲、安慰剂对照、多中心临床试验。
Lancet. 2020 May 16;395(10236):1569-1578. doi: 10.1016/S0140-6736(20)31022-9. Epub 2020 Apr 29.
7
Hypoxemia in COVID-19; Comment on: "The neuroinvasive potential of SARS-CoV2 may play a role in the respiratory failure of COVID-19 patients".新型冠状病毒肺炎中的低氧血症；评论：“SARS-CoV-2的神经侵袭潜力可能在新型冠状病毒肺炎患者的呼吸衰竭中起作用”
J Med Virol. 2020 Oct;92(10):1705-1706. doi: 10.1002/jmv.26020. Epub 2020 Jul 27.
8
Triple combination of interferon beta-1b, lopinavir-ritonavir, and ribavirin in the treatment of patients admitted to hospital with COVID-19: an open-label, randomised, phase 2 trial.干扰素 beta-1b、洛匹那韦利托那韦和利巴韦林三联治疗住院 COVID-19 患者：一项开放标签、随机、2 期试验。
Lancet. 2020 May 30;395(10238):1695-1704. doi: 10.1016/S0140-6736(20)31042-4. Epub 2020 May 10.
9
Clustered cases of acral perniosis: Clinical features, histopathology, and relationship to COVID-19.肢端冻疮样病变聚集性病例：临床特征、组织病理学及与新型冠状病毒肺炎的关系
Pediatr Dermatol. 2020 May;37(3):419-423. doi: 10.1111/pde.14227.
10
Incomplete Kawasaki Disease in a Child with Covid-19.一名感染新冠病毒的儿童患不完全川崎病
Indian Pediatr. 2020 Jul 15;57(7):680-681. doi: 10.1007/s13312-020-1900-0. Epub 2020 May 9.
Zotero 插件